YO1 - Comparison of Disease Free Survival (DFS) in Lymph Node Positive Breast Cancer Patients based on Metastatic Lymph Node Ratio (MLNR)
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Breast Cancer, Locally Advanced
|Presenter||Pegah Gorji Bayani|
P. Gorji Bayani, A. Ghanbari-Motlagh, P. Azadeh, F. Hosseini Kamal
Comparison of Disease Free Survival (DFS) in Lymph Node Positive
Breast Cancer Patients based on Metastatic Lymph Node Ratio (MLNR)
The prevalence of breast cancer varies among countries and regions. Metastasis to the axillary lymph nodes is a key indicator of prognosis in breast cancer. This retrospective study investigated the prognostic value of the metastatic lymph node ratio (MLNR) compared with other clinicopathologic factors in Persian breast cancer patients.
This was a retrospective study that evaluated the prognostic value of MLNR compared with other factors (age, N stage, T stage, hormone receptor, grade, HER-2, LVI, PNI) in a cohort of lymph node positive breast cancer patients. The medical records of 563 female patients who were treated in Jorjani Center from 1997 to 2006 were reviewed and analyzed.
Statistical analyses were performed with SPSS 19. Kaplan-Meier analysis with log-rank test was used to determine 5 year disease free survival (DFS) curves. Univariate and multivariate Cox proportional hazards analyses were performed to identify prognostic value of MLNR and other clinicopathologic factors for patients with node positive breast cancer patients.
Results & Conclusion:
We defined cutoff points (0.19 in all patients and 0.3 for insufficient lymph node dissected patients) for MLNRs and divided the population into those at low risk and high risk. The MLNR groups had significantly different 5-years DFS and were more accurate than other factors for predicting DFS. Our findings support the use of MLNR as a predictor of 5-year DFS in patients with node positive breast cancer, and that MLNR is superior to other factors in determining prognosis.
Breast cancer, disease free survival, metastatic lymph node ratio